Business Wire

Syniverse and Telefónica Collaborate to Offer New Secure Global Messaging Service

28.10.2019 10:05:00 EET | Business Wire | Press release

Share

At the GSMA WAS#10 conference and exposition, Syniverse, the world’s most connected company, announced it is developing a secure global messaging solution that is designed to help brands keep text messaging clear of inherent security risks that come when sending messages over the internet and without proper user authentication.

To protect against vulnerabilities in text messaging, Syniverse is collaborating with Telefónica to offer businesses a global cloud-based messaging platform that runs over a private network with end-to-end encryption of actual messages and messages in transit. The network operates separately from the public internet using private addressing schemes that make it invisible to those with malicious intent.

What used to be considered “secure enough” for text messaging is no longer adequate for keeping information safe from the advanced techniques of fraudsters and hackers. That’s why companies like Telefónica International in Latin America and Europe are turning to Syniverse to help manage mobile communications by confirming customer identity and consent, and securely transmitting customer and business data.

The mobile attack rate in Latin America, where the Syniverse solution will initially launch, is 8.9 percent, according to Lexis Nexis. Payment transactions, logins and new account creations are being targeted by fraudulent bots, and by the spoofing of internet protocol (IP) addresses, devices and identities. With this secure global messaging solution, Syniverse and Telefónica will protect customers and mobile operators from these attacks as well as an array of other cyberattacks, including phishing, whaling, denial-of-service, and man-in-the-middle incidents.

Latin America isn’t the only region that’s targeted by malicious actors. In the U.S. last year, there were 16.7 million people affected by account takeover fraud, according to Javelin Research. In one case, a leading bank lost $15 million in fraudulent withdrawals due to poor transport, application and security encryptions. Attackers fraudulently assumed the identity of one of the bank’s customers to access the payment network before making fake withdrawals from multiple bank branches.

The need for the secure alternative that Syniverse will offer extends beyond the banking industry. The potential for loss affects any company that relies on digital communications. Text messages can be hacked to access financial or operational information or even to control networks, systems and databases. Whether it’s an e-commerce platform that sends one-time password texts to authenticate customers or a government agency deploying surveillance drones, a variety of processes used by different industries are at risk.

Syniverse will safeguard the customer experience and drastically decrease business risks by offering full-network-layer encryption all the way through a company application to the mobile operator with segmenting isolation in two areas. Also, automated alarming will set off if network end points deviate from expected communications behavior.

Product availability will be based on the number of mobile network operators connected to the secure global messaging solution, which will continually expand. Companies looking to secure their communications can contact Syniverse here.

CLICK TO TWEET : .@Syniverse & @telefonicab2b collaborate to make #textmessaging safer from hackers and fraudsters #enterprises. #cybersecurity #fraud @GSMA #WAS10 http://ow.ly/ZT8q50wUcpQ

Quote

  • John Wick, Senior Vice President and General Manager, Global Product, Syniverse

“Any device that is capable of sending and receiving text messages over an unsecured network is at risk of cyberattack. To minimize this risk, Syniverse and Telefónica are leading the way to secure the messaging environment so that sensitive information is protected at each stage of its journey as a message is sent from a brand, passed through a mobile network, and received by an end device.”

Supporting Resources

About Syniverse

Syniverse is the world’s most connected company – we pioneer innovations that take business further. Our secure, global network reaches billions of people and devices. Our engagement platform powers the customized experiences of the future. And the millions of secure transactions we drive every minute are revolutionizing how goods and services are exchanged. We have always led companies to reimagine the boundaries of possibility. Today we’re delivering on opportunities with the power to change the world.

About Telefonica Business Solutions

Telefónica Business Solutions a leading provider of a wide range of integrated communication solutions for the B2B market, manages globally the Enterprise (Large Enterprise and SME), MNC (Multinational Corporations), Wholesale (fixed and mobile carriers, ISPs and content providers) and Roaming businesses within the Telefónica Group. Business Solutions develops an integrated, innovative and competitive portfolio for the B2B segment including digital solutions (Big Data, Cloud, IoT or Security) and telecommunication services (international voice, IP, bandwidth capacity, satellite services, mobility, integrated fixed, mobile, IT services and global solutions). Telefonica Business Solutions is a multicultural organization, working in over 40 countries and with service reach in over 170 countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kevin Petschow
Syniverse
+1.813.637.5084
kevin.petschow@syniverse.com

Matt Burrows
The Hoffman Agency (for Syniverse)
+1.408.286.2611
mburrows@hoffman.com

Telefónica
Corporate Communications Department
+34 91 482 3800
prensatelefonica@telefonica.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye